BRIEF-Five Prime Therapeutics announces completion of enrollment for the phase 2 of the ongoing trial of Cabiralizumab
April 10 Five Prime Therapeutics Inc:
* Five Prime Therapeutics announces completion of enrollment for the phase 2 part of the ongoing trial of cabiralizumab for the treatment of pigmented villonodular synovitis (PVNS)
* Five Prime Therapeutics Inc - Five Prime plans to seek regulatory feedback on design of a pivotal trial
* Five Prime Therapeutics - plans to present initial data from phase 2 part of trial at 2017 American Society Of Clinical Oncology (ASCO) annual meeting Source text for Eikon: Further company coverage: